Opendata, web and dolomites

ZECARDIO

Cardiotoxicity High-throughput screening (HTS) with zebrafish embryo

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ZECARDIO" data sheet

The following table provides information about the project.

Coordinator
ZECLINICS SL 

Organization address
address: CTRA DE CAN RUTI, CAMI DE LES ESCOLES, S/N LABORATORI P0-8, EDIFICI IGTP MUNTANYA
city: BARCELONA
postcode: 8916
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.zeclinics.com/zeproducts/zecardio/
 Total cost 1˙867˙186 €
 EC max contribution 1˙867˙186 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-04-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ZECLINICS SL ES (BARCELONA) coordinator 1˙867˙186.00

Map

 Project objective

The complex nature of pharmaceutical new molecules generation, both in terms of R&D process and regulatory requirements, indicates a huge need for innovative tools/services for optimal delivery to patients of novel medicines in the fastest and cheapest manner. The pharmaceutical industry strives continuously to produce new, safer and more efficacious drugs for unmet needs, evolving different synthesis techniques, expanding numbers of leads for potential drug candidates. However, this abundance has also created a new set of challenges in efficient processing of drug libraries for target validation and toxicity assessment. High-throughput screening (HTS) is thought to be key in handling this flow of new potential therapeutics in a systematic and time-efficient manner. But, there is a strong evidence that in vitro cell-based assays and subsequent preclinical in vivo studies do not yet provide sufficient pharmacological and toxicity data or reliable predictive capacity for understanding drug candidate performance in vivo. The model developed by ZeClinics with specific focus on cell and molecular interactions and physiological parameters improves this situation and helps to determine the corresponding responses to bioactive agents. The aim of ZeCardio project is to use zebrafish model to develop HTS of large libraries in live organism for cardiotoxicity assessment. Our complete system analyses the impact of drugs and diseases in heart performance (Heart rate, Arrytmia, AV Blockage and Ejection fraction) and the performance of the vascular system (Blood flow and vasodilatation/constriction).

 Deliverables

List of deliverables.
ZeCardio Pilot test Demonstrators, pilots, prototypes 2019-09-13 11:18:03

Take a look to the deliverables list in detail:  detailed list of ZECARDIO deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Carles Cornet, Vincenzo Di Donato, Javier Terriente
Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline
published pages: , ISSN: 1663-9812, DOI: 10.3389/fphar.2018.00703
Frontiers in Pharmacology 9 2019-09-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ZECARDIO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ZECARDIO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More